-+ 0.00%
-+ 0.00%
-+ 0.00%

MiNK Therapeutics Presents Updated Clinical Results Evaluating Agent-797, Alone And In Combination With Anti-PD-1 Therapy, In Patients With Advanced Solid Tumors Refractory To All Approved Treatments At SITC 2025

Benzinga·11/07/2025 14:07:38
Listen to the news
  • Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1
  • Evidence of immune activation and tumor-immune remodeling underscore agenT-797's potential to restore responsiveness in PD-1–resistant disease
  • Favorable safety and reproducible activity reinforce MiNK's leadership in allogeneic iNKT cell therapy

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to reconstitute immunity to treat cancer and immune disorders, today announced updated clinical results evaluating agenT-797, alone and in combination with anti-PD-1 therapy, in patients with advanced solid tumors refractory to all approved treatments presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 (Late Breaking Abstract #1344).

The results demonstrate durable survival, deep and lasting responses, and broad immune restoration in patients with solid tumors that had progressed on checkpoint inhibitors and multiple prior therapies.